Scientific article
English

Infliximab then efalizumab, the 'hit and run' approach does not work

Published inDermatology, vol. 216, no. 2, p. 171-172
Publication date2008
Abstract

BACKGROUND: In a previous paper we described 2 patients treated with a sequential biologic therapy for chronic plaque psoriasis. We used infliximab as an induction treatment followed by efalizumab. We extended this approach to 3 other patients. OBJECTIVE: The purpose was to show the feasibility of a sequential approach with biologicals. METHODS: Five patients received three infusions of infliximab followed by weekly injections of efalizumab from week 10 on. RESULTS: The most important findings, summarized in a table, show that none of the patients continued the treatment for more than a year either because of non-responsiveness or because of spontaneous stopping. Moreover, 4 out of 5 patients did not respond or had serious adverse events on reintroduction of infliximab. CONCLUSION: Overall, we cannot recommend sequential therapy using infliximab and efalizumab.

Keywords
  • Adult
  • Antibodies Monoclonal/therapeutic use
  • Cell Migration Inhibition
  • Dermatologic Agents/therapeutic use
  • Disease Progression
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Psoriasis/drug therapy
  • Time Factors
  • Tumor Necrosis Factor-alpha
Citation (ISO format)
BARDE, Caroline, THIELEN, A M., SAURAT, Jean-Hilaire. Infliximab then efalizumab, the “hit and run” approach does not work. In: Dermatology, 2008, vol. 216, n° 2, p. 171–172. doi: 10.1159/000111517
Main files (1)
Article (Accepted version)
accessLevelRestricted
Identifiers
Journal ISSN1018-8665
582views
0downloads

Technical informations

Creation11/02/2009 14:02:00
First validation11/02/2009 14:02:00
Update14/03/2023 15:00:13
Status update14/03/2023 15:00:13
Last indexation29/10/2024 11:08:00
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack